Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 17;15(14):4467-4476.
doi: 10.7150/jca.84832. eCollection 2024.

Genomic Alterations Correlated to Trastuzumab Resistance and Clinical Outcomes in HER2+/HR- Breast Cancers of Patients Living in Northwestern China

Gang Ma  1 , Binliang Huo  1 , Yanwei Shen  1 , Xulong Zhu  1 , Chong Cheng  1 , Wensheng Li  2 , Wei Cao  1 , Jianhui Li  1
Affiliations

Genomic Alterations Correlated to Trastuzumab Resistance and Clinical Outcomes in HER2+/HR- Breast Cancers of Patients Living in Northwestern China

Gang Ma et al. J Cancer. .

Abstract

Anti-HER2 therapy has significantly improved the survival rates of patients with HER2+ breast cancer. However, a subset of these patients eventually experience treatment failure, and the underlying genetic mechanisms remain largely unexplored. This underscores the need to investigate the genomic heterogeneity of HER2+ breast cancer. In this study, we focus on HER2+/HR- breast cancer, as it differs from HER2+/HR+ breast cancer in terms of genetic and biological characteristics. We performed gene-targeted genome sequencing on 45 HER2+/HR- breast cancer samples and identified 650 mutations across 268 cancer-related genes. TP53 (71.1%) and PIK3CA (35.6%) were the most frequently mutated genes in our sample. Additionally, ERBB2 (77.8%), CDK12 (42.2%), and MYC (11.1%) exhibited a high frequency of copy number amplifications (CNAs). Comparative analysis with two other HER2+/HR- breast cancer cohorts revealed that our cohort had higher genetic variation rates in ARID1A, PKHD1, PTPN13, FANCA, SETD2, BRCA2, BLM, STAG2, FAT1, TOP2A, POLE, ATM, KMT2B, FGFR4, and EPAS1. Notably, in our cohort, NF1 and ATM mutations were more prevalent in trastuzumab-resistant patients (NF1, p=0.016; ATM, p=0.006) and were associated with primary trastuzumab resistance (NF1, p=0.042; ATM, p=0.021). Moreover, patients with NF1 mutations (p=0.009) and high histological grades (p=0.028) were more likely to experience early relapse. Ultimately, we identified a unique cancer-related gene mutation profile and a subset of genes associated with primary resistance to trastuzumab and RFS in patients with HER2+/HR- breast cancer in Northwest China. These findings could lay the groundwork for future studies aimed at elucidating the mechanisms of resistance to trastuzumab and improving HER2-targeted treatment strategies.

Keywords: Breast cancer; Genomic profiling; HER2 positive; Trastuzumab resistance.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Figures

Figure 1
Figure 1
Summary of the somatic mutations and Indels of all 45 patients with HER2+/HR- breast cancer in Northwestern China. (HER2-TR = HER2+/HR- breast cancer with primary trastuzumab-resistant status, HER2-TS = HER2+/HR- breast cancer with tastuzumab sensitive status).
Figure 2
Figure 2
Comparison of gene mutations and CNAs between our cohort and the two published HER2+/HR- breast cancer cohorts (TCGA PanCancer Atlas and METABRIC): (a) Comparison of the top twenty mutated genes among the three cohorts (the blue, yellow, and green colors represent the top twenty mutated genes of the three cohorts individually); (b) Comparison of top ten CNAs among the three cohorts (the blue, yellow, and green colors indicate the top ten CNAs of the three cohorts individually).
Figure 3
Figure 3
Summary of hot spot mutations of eight highly mutated genes (Containing TP53, PIK3CA, ARID1A, FAT1, NF1, ATM, PKHD1, and FANCA) in the HER2+/HR- breast cancer cohort of Northwestern China. The mutations are shown in the lollipop graphs.
Figure 4
Figure 4
KEGG enrichment of mutation pathway(a) and gene association and mutual exclusion (b) in the HER2+/HR- breast cancer cohort of Northwestern China.
Figure 5
Figure 5
Comparison of mutation genes(a)and KEGG pathway(b) between primary trastuzumab-resistant and non-resistance groups of the HER2+/HR- breast cancer cohort in Northwestern China.
Figure 6
Figure 6
The Kaplan-Meier curves of mutated NF1 gene (a)and histological grade status(b) on RFS of the patients with HER2+/HR- breast cancer in Northwestern China.
See this image and copyright information in PMC

References

    1. Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R. et al. Cancer incidence and mortality in China, 2016. Journal of the National Cancer Center. 2022;2:1–9.
    1. Loibl S, Gianni L. HER2-positive breast cancer. The Lancet. 2017;389:2415–29. - PubMed
    1. Thanopoulou E, Khader L, Caira M, Wardley A, Ettl J, Miglietta F. et al. Therapeutic strategies for the management of hormone receptor-positive, human epidermal growth factor receptor 2-Positive (HR+/HER2+) breast cancer: A review of the current literature. Cancers. 2020;12:3317. - PMC - PubMed
    1. Vernieri C, Milano M, Brambilla M, Mennitto A, Maggi C, Cona MS. et al. Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives. Critical reviews in oncology/hematology. 2019;139:53–66. - PubMed
    1. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ. et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118–45. - PubMed